Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDMETH trial in pulmonary sarcoidosis
NL-OMON49109Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate and prednisone in pulmonary sarcoidosis, sponsored by Erasmus MC. Primary endpoint: Change in forced vital capacity. Started Jul 2020; status: recruiting.
02
Drugs
methotrexateprednisone
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NL-OMON49109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49109.